The Intrathecal Pumps Market size was valued at USD 0.32 billion in 2021 and is projected to grow from USD 0.38 Billion in 2022 to USD 3.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.1% during the forecast period (2024 - 2032). The increasing number of pharmaceutical research and development activities, growing demand for intrathecal pumps, and increasing healthcare expenditure deployment are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
In general, intrathecal pumps are used to manage cancer pain, pain following unsuccessful procedures, or situations requiring high dosages of opioids and morphine. These surgically implanted pumps are put beneath the skin of the abdomen and use a catheter to deliver medication to the patient's spinal cord's cerebrospinal fluid. This makes it possible for the pump to administer a drug dose that is more precise than when taken orally. Intrathecal pump demand is driven by the rising incidence of chronic diseases, including cancer, chronic pancreatitis, and other postoperative pain conditions where patients experience constant, excruciating back pain. Additionally, the prevalence of spasticity symptoms is rising, fueling this market's expansion.
The rising incidence of chronic illnesses like cancer pain and other pain-producing conditions like postoperative pain, wherein the patient has ongoing and severe back pain, are major reasons propelling the expansion of intrathecal pumps. One of the main drivers propelling the market is the rising need for tailored medication delivery methods and technological advances in intrathecal pumps. Despite communication issues with medical staff, ideal scores were kept at the start of the pandemic and one year later without any discernible changes. To avoid viral transmission during the pandemic, most chronic pain services were labeled as non-urgent, and all the intrathecal pump (ITP) refill procedures were insufficient or stopped, which hindered market expansion. However, services have slowly restarted worldwide, and the market is anticipated to expand.
Additionally, it has been noted that makers of intrathecal pumps are advancing devices with longer battery lives, which could reduce the number of additional surgical procedures needed to replace failing pumps. Growth in the sector is anticipated to be fueled by an increase in cases of pain disorders. Only severe pain that other painkillers cannot control is treated with morphine extended-release capsules and tablets. The requirement for morphine solutions for pain relief is anticipated to rise as the incidence of chronic diseases like cancer, arthritis, and other illnesses rises. Cancer discomfort is becoming more common as oncologic patients' rates of survival increase.
The increasing prevalence of chronic disease such as cancer, chronic pancreatitis and other pain associated with post operative pain where the patient feels continual and severe back pain are boosting the market demand of intrathecal pumps. In addition, rising cases of spasticity symptoms which are further boosting the growth of this market. For Instance, in 2020, as per the American Association of Neurological Surgeons around 12 million population in the world suffered from spasticity symptoms, including patients with multiple sclerosis, with, spinal cord injury, traumatic brain injury, cerebral palsy, and stroke. Moreover, according to the Cancer Research UK, an estimate of 38 and of 100 people with cancer suffered from moderate to severe pain as well as 65 out of 100 people suffered from pain associated with advance cancer in 2020. Furthermore, as per the Centers for Disease Control and Prevention estimate that incidence of chronic pancreatitis ranges from 5 to 12/100,000 people as well as prevalence approximate 50/100,000 persons in 2021.
Figure 1: Global Intrathecal Pumps By Product Class, 2023 & 2030 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The market segments of intrathecal pumps, based on product class is further segmented into baclofen, hydromorphone, morphine, bupivacaine, and others . The morphine segment is to hold the majority share in 2021 in the Intrathecal Pumps Market revenue. This is due to the morphine is considered the gold standard in intrathecal drug administration due to its strong receptor affinity, stability, and most preferred drug. Furthermore, morphine has received US FDA approval for long term intrathecal pain condition in the US. Moreover, the long-term intrathecal morphine has lesser side effects as compared to systemic opioids which propel the growth of this segment. In addition, Bupivacaine is expected to grow at a healthy CAGR of 6.60% over the forecast period. Bupivacaine is considered an exceptional extra medication in intrathecal therapy.
In October 2019, Flowonix Medical received US FDA approval for Prometra II 40 ml programmable pump for use with intrathecal baclofen. This product launch permitted the company to offer a Prometra system to serve 40 ml pumps to cancer patients.
The Intrathecal Pumps Market segmentation is based on applications that includes, pain management and spasticity management. The pain segment has dominated the market in 2021 and is projected to be the fastest-growing segment during the forecast period, 2022-2030. This is due to the increasing prevalence of chronic and acute disorders, such as pain associated with cancer, and other pain such as back surgery syndrome which is the major factor that boost the growth of segment. Thus, intrathecal pumps are most suited for patients suffering from pain associated disorders.
Figure 2: INTRATHECAL PUMPS MARKET, BY APPLICATION, 2023 & 2030 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Market segmentation of Intrathecal Pumps is based on end-user that includes hospitals & clinics, ambulatory surgery centers. The hospitals & clinics segment has dominated the market in 2021 and is projected to be the fastest-growing segment during the forecast period, 2022-2030. This is due to the availability of highly skilled medical professions, increasing patient pool in hospitals. Moreover, the increasing government support for development of better medical facility also drives the growth of hospitals and clinics segment in market.
February 2020:
In February 2020, Flowonix received US FDA approval for the Prometra II Programmable Pump System for use with intrathecal baclofen to treat critical spasticity in diseases, including cerebral palsy (CP).
News:
To tackle problems like intrathecal and nanoparticle drug delivery, Eli Lilly is investing an additional $50 million in its research partnership with Purdue University. The pharmaceutical company has agreed to collaborate with its partner for five years. With Purdue's expertise, the drugmaker might now enhance the delivery of injectable medications thanks to that collaboration. Lilly identified the institution as a potential supporter of its objectives to lessen pain, reduce the need for injections, improve patient compliance, and improve overall health. Lilly has reached an agreement to prolong the research cooperation by five years as the original agreement comes to an end. To maintain the partnership and cooperate with Purdue on genetic healthcare, intrathecal delivery, and nanoparticle medication delivery, Big Pharma has signed a fresh $50 million master agreement.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America intrathecal pumps market accounted for USD 0.32 billion in 2021 and is expected to exhibit a 5.25% CAGR during the study period. This is attributed to the presence of major key players, the availability of well-developed primary, secondary, and tertiary care hospitals provide supported the market of intrathecal pumps in North America region. In addition, favorable government policy and strong reimbursement network are majorly driving the market growth of intrathecal pumps. Thus, favorable government policy as well as reimbursement policy increasing interest of major key players for investment in research and development activity is likely to drive the intrathecal pumps market growth in the North America region.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: INTRATHECAL PUMPS MARKET SHARE BY REGION, 2023 & 2030 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe intrathecal pumps market is expected to account for the second-largest market share due to the increasing research and development activity, increasing cases of cancer associated pain which directly influence the demand of market of intrathecal pumps in Europe region. Furthermore, the Germany market of intrathecal pumps is expected to hold third position for the market share, and the UK country consider as fastest growing country in the market of intrathecal pumps which holds fourth position in Europe region. Moreover the France market of intrathecal pumps will hold the least market share in Europe region.
The Asia-Pacific intrathecal pumps market is expected to fastest growing CAGR from 2022 to 2030. This is due to the growing research and development activity, increasing healthcare expenditure in the Asia Pacific which is expected to propel the product demand. Moreover, the increasing number of investigational compounds and rising preclinical trials in the Asia-Pacific region is further boosting the market growth of intrathecal pumps.
In addition, rising statergic alliance such as mergers, acquisition, collaboration, and partnership by key players in Asia-Pacific region is boosting the business in Asia-Pacific region. Further increasing population which leads to increased risk of pain associated chronic diseases due to the changing lifestyle pattern, rising inclination towards western lifestyle as well as changing food habits pattern in Asian population leads to risk of life-threatening diseases which is positively impact on the market demand of intrathecal pumps in Asia-Pacific region. In addition, Japan holds the largest market share in intrathecal pumps due to the rising geriatric population and China is expected fastest growing market in Asia-Pacific region.
The Rest of the World includes the Middle East, Africa, and Latin America. Middle East holds the largest market share in Rest of the World due to the improving medical infrastructure facilities as well as availability of highly skilled medical staff, government initiative for healthcare system development drives the market demand of intrathecal pumps in the region.
Intrathecal Pumps Key Market Players & Competitive Insights
The market of intrathecal pumps is characterized by the presence of many global, regional, and local vendors catering to the demand created by medical devices and research scientists operating in the industry. The intrathecal pumps market players heavily invest in research and development activity across the globe with varied product portfolios. Companies such as Novartis (Switzerland), Teleflex, Inc. (US), Flowonix Medical, Inc. (US), Medtronic Plc (Ireland), Johnson & Johnson (US) dominate the market of intrathecal pumps due to strong research and development activity, financial stability, statergic alliance, and wide business presence in across the globe. The key players are focused on the development of new products. Moreover, they adopt growth initiatives, such as collaboration, product launches, mergers, and acquisition, to strengthen their market position and gain a large customer base.
One of the primary business strategies adopted by manufacturers in the global intrathecal pumps industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. Flowonix Medical, Inc (US) is a well-established medical company which is involved in manufacturing of medical devices. The company majorly offers products for chronic disease management. It provides products from across the globe. The company mainly distributes targeted drug delivery platform for chronic disease pain management. Moreover, the company has US patented programmable valve pumps, implantable, refillable pumps, long life power supplies for implantable pumps, septumless implantable pumps, low power electromagnetic valves, and pump diagnostic systems. In November 2019, Flowonix Medical Inc received US FDA approval to market Prometra II Programmable Pump System for utilize with intrathecal baclofen. The company introduced the Prometra II 40mL pump to the US market. This device offers clinicians and patients a choice between 20 ml and 40 ml capacities when prefer an intrathecal pump delivery device. By this product launch company enhance market business presence in US.
Teleflex Incorporated is a medical technology company which design and develop various healthcare products. The company product portfolio is diverse in the area of emergency medicine, surgical, vascular access, interventional cardiology and radiology, anaesthesia and respiratory care. It offers product under the segment of surgical, respiratory, interventional urology, and urology. The company operated its business in more than 150 countries.
Key Companies in the Market of Intrathecal Pumps Include.
Intrathecal Pumps Industry Developments
September 2020: Novartis Gene Therapies begin a new pivotal confirmatory study to calculate the use of AVXS-101 intrathecal (IT) formulation in older patients with Spinal Muscular Atrophy (SMA) to further regulatory submission for AVXS-101.
January 2018: Medtronic received US FDA approval for a novel clinician programmer for use with SynchroMed (TM)II intrathecal drug delivery system. By this product approval company expand their business in US.
| Report Attribute/Metric | Details |
| Market Size 2021 | USD 0.24 billion |
| Market Size 2022 | USD 0.28 billion |
| Market Size 2030 | USD 3.8 billion |
| Compound Annual Growth Rate (CAGR) | 5.1% (2023-2032) |
| Base Year | 2021 |
| Forecast Period | 2023-2032 |
| Historical Data | 2018 & 2020 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Class, Application, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Medtronic Plc. (US), Flowonix (US), Medallion Therapeutics (US), Arrow International, Inc (US), Tricumed GmbH (Germany), Codman & Shurtleff, Inc (US), Abbott (US), Baxter International Inc (US), Teleflex Incorporated (US), Durect Corporation (US). |
| Key Market Opportunities | Technological development in intrathecal pumps |
| Key Market Dynamics | Rising incidence of chronic disorders Growing demand for intrathecal pumps Increasing healthcare expenditure |
Frequently Asked Questions (FAQ) :
The global Intrathecal Pumps Market is anticipated to reach USD 3.8 billion at a CAGR of 5.1% during the forecast period of 2023 to 2032.
The U.S. intrathecal pumps market is anticipated to reach USD 3.8 billion at a CAGR of 5.1% during the forecast period of 2023 to 2032.
The global intrathecal pumps marketIntrathecal Pumps Market is expected to register a CAGR of 5.1% during the forecast period of 2024 to 2032.
The North America intrathecal pumps market accounted for USD 0.12 billion in 2021 and is expected to exhibit a 4.9% CAGR during the study period.
Medtronic Plc. (US), Flowonix (US), Medallion Therapeutics (US), Arrow International, Inc (US), Tricumed GmbH (Germany), Codman & Shurtleff, Inc (US), Abbott (US), Baxter International Inc (US), Teleflex Incorporated (US), Durect Corporation (US).
The baclofen segment held the majority share in 2021 contributing to around 72.56% with respect to the global intrathecal pumps marketIntrathecal Pumps Market.
The hospitals & clinics segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
